Introduction
============

Tetrabenazine (TBZ) was initially synthesized in the 1950s by O Schneider and A Brossi at the research laboratory of Hoffmann-La Roche in Basel. They created TBZ as an antipsychotic drug as part of their research into simpler chemical compounds with reserpine-like activity. TBZ was studied in a number of controlled trials in schizophrenia patients with equivocal results ([@b60-ndt-3-545]; Weckorciez 1960; [@b26-ndt-3-545]). Later clinicians came to favor the use of dopamine receptor blocking drugs (DRBD), like phenothiazines, for treating psychosis given the evidence of better efficacy ([@b1-ndt-3-545]). However, as with many other drugs, when TBZ was tested for indications other than the original ones the preliminary results provided support for its use in disorders characterized by abnormal hyperkinetic involuntary movements, drug induced or primary. During the last two decades TBZ has been used in a multitude of movement disorders: tardive dyskinesia ([@b9-ndt-3-545]; [@b38-ndt-3-545]; [@b59-ndt-3-545]; [@b65-ndt-3-545]) dystonia ([@b32-ndt-3-545]; [@b46-ndt-3-545]; [@b57-ndt-3-545]) and tremor ([@b62-ndt-3-545]), choreic syndromes ([@b13-ndt-3-545]; [@b39-ndt-3-545]), primary dystonia ([@b3-ndt-3-545]; [@b10-ndt-3-545]; [@b32-ndt-3-545]; [@b4-ndt-3-545]; [@b57-ndt-3-545]), secondary dystonia ([@b7-ndt-3-545]) and tic disorders (Vieregge 1987; [@b23-ndt-3-545]; [@b54-ndt-3-545]).

Chemistry
=========

TBZ, also named Ro 1-9569 by Hoffmann-LaRoche, Inc., is a benzoquinolizine derivative with the following formula, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo\[a\]quinolizine. It is a white crystalline substance with a bitter taste. The molecule is shown in [Figure 1](#f1-ndt-3-545){ref-type="fig"}. It can be isolated from alkalinized biological material by extraction into heptane into diluted hydrochloric acid and assayed fluorometrically ([@b45-ndt-3-545]). Chromatographic analysis of TBZ reveals peak fluorescence at 282 nm ([@b49-ndt-3-545]). Based on the acid-basic transition, TBZ is characterized by a pKa of 6.0 ([@b55-ndt-3-545]).

Pharmacodynamics and pharmacokinetics
=====================================

TBZ is readily absorbed from the intestinal tract. After intravenous administration of TBZ tagged with tritium in humans, 54% was excreted in urine after 48 hours ([@b63-ndt-3-545]).

TBZ enters the rabbit brain rapidly after intravenous administration attaining maximal levels of about 34 micrograms per gram within 10 minutes. In other tissues maximal concentration is seen within 15--30 minutes, latest in fat tissue (with concentrations in fat tissue coming last). The half life in various tissues (when given intravenously to rabbits) ranges from 0.9--2.7 hours, with the longest half-life being in fat tissue. After 24 hours, TBZ will have disappeared from most tissues, brain tissue included ([@b45-ndt-3-545]). TBZ has a relatively low bioavailability, 0.049 ± 0.032 ([@b48-ndt-3-545]).

TBZ is metabolized into two compounds: α- and β-dihydrotetrabenazine (DTBZ); α-DTBZ being the active compound, whereas β-DTBZ is biochemically inert. α-DTBZ has a high bioavailability because it is less protein-bound (44%--59%) compared to TBZ (83%--88%) ([@b48-ndt-3-545]). α-DTBZ has higher plasma levels than TBZ and the half-life is longer, 10 hours versus 6 hours (in humans) ([@b48-ndt-3-545]). Therefore it has to be administered two to three times a day.

Acute toxicity in mice LD 50 is found to be 150 mg/kg by intravenous injection, 400 mg/kg by subcutaneous injection and about 550 mg/kg by oral administration, being about ten times less toxic than reserpine, another cathecolamine depletor). Toxic doses produce spasms with respiratory inhibition and opisthotonus. Chronic toxicity observed in rats given a daily dose of 8--15 mg/kg daily in their food for 13 weeks was well tolerated and growth was little influenced and neither blood nor organ examinations showed any abnormality (Lingierde 1963). TBZ crosses the placenta but no case of teratogenicity has been reported in humans. It is also excreted in breast milk and therefore breastfeeding should be avoided while taking TBZ ([@b48-ndt-3-545]).

Mechanism of action
===================

The mechanism of action of TBZ is well known ([@b43-ndt-3-545]). It acts mainly as a reversible high affinity inhibitor of monoamine uptake into granular vesicles of presynaptic neurons and secondary depletion at low doses, as well as a weak D~2~ postsynaptic receptor blocker in high doses ([@b47-ndt-3-545]) TBZ depletes all three monoamines, but particularly dopamine ([@b44-ndt-3-545]). One in vivo study of rats showed that TBZ decreased dopamine levels by 40%, serotonin by 44%, and norepinephrine by 41% in the brain ([@b30-ndt-3-545]).

The effect of a seven-day repetitive administration of TBZ in rats was investigated by examining the locomotive behavior and histomorphological findings of substantia nigra in rats. These studies compared the effect of a single dose of TBZ which caused decrease of voluntary movements and no histological changes versus repetitive administration of TBZ which demonstrated irreversible and significant changes in spontaneous locomotion as well as histological changes in the neurons of the substantia nigra pars compacta. The results suggest that this could be a new and useful model for the behavioral characteristics and anatomical pathology of Parkinson's disease as one of the oxidative stress models induced by abnormal dopamine metabolism ([@b51-ndt-3-545]).

In an autopsy study of Huntington's disease (HD) patients, those patients who had received TBZ displayed a greater overall depletion of monoamines than patients not exposed to TBZ, primarily in the caudate, but also, to a lesser degree, in the amygdala, hippocampus, and temporal lobe ([@b42-ndt-3-545]). PET studies w/11-C-raclopride show a 28% reduction in striatal binding after TBZ.

α-DTBZ has been shown to inhibit monoamine uptake driven by a transmembrane proton elecrochemical gradient generated by an ATP-ase proton pump using a special transporter (VMAT). In rat fibroblasts the central neural transporter VMAT2 is inhibited by TBZ, but the peripheral endocrine specific VMAT1 is not ([@b33-ndt-3-545]; [@b8-ndt-3-545]). VMAT2 is a large protein with 12 transmembrane helices encoded by the VMAT2 gene localized to chromosome 10q25. VMAT2 is expressed primarily in the brain. VMAT1 is encoded by a gene on chromosome 8p21.3 and is expressed in the periphery ([@b14-ndt-3-545]).

The dual effects of TBZ are thought to be responsible both for its therapeutic effects as well as its side effects.

Tetrabenazine versus reserpine
==============================

The pharmacologic agent most similar to TBZ is reserpine (R). Both TBZ and R seem to reduce cells' capacity to store monoamines, therefore causing a depletion of the brain storage of these amines and in the case of Reserpine a depletion of the amines in the peripheral sites. Both drugs act centrally on VMAT2, but reserpine also inhibits VMAT1 peripherally, which may explain the higher frequency of hypotension and gastrointestinal side effects it causes. While reserpine binds irreversibly to both VMAT's, TBZ binds reversibly only to VMAT2. TBZ displays a much shorter half life than reserpine (hours as opposed to days) and has a more rapid onset of action. This confers an advantage on TBZ in the clinical setting as its efficacy can be assessed more rapidly and its side effects abate more rapidly upon discontinuation of drug usage. Differences summarized in [Table 1](#t1-ndt-3-545){ref-type="table"}.

Huntington's disease
====================

HD is a genetic neurological disease, which manifests a triad of psychiatric, cognitive and movement disorders. HD is inherited in an autosomal dominant fashion with complete penetrance. The prevalence rate in the United States has been estimated at 5--10 per 100,000 (Jancovic et al 1995). Genetic studies of families with a very high prevalence and incidence of HD from the Lake Maracaibo area in Venezuela led to the discovery of an unstable trinucleotide (CAG) repeat present in the gene on chromosome 4. The number of CAG repeats in normal subjects is up to 29 repeats, while the presence of 36 or more CAG repeats ensures the development of HD ([@b66-ndt-3-545]). The phenomena of anticipation and paternal imprinting have been well described in HD. The disease often presents with psychiatric problems or one type of hyperkinetic movement disorder, usually chorea. HD patients slowly progress over 15--20 years to a bedridden state. In advanced stages functional disability develops with dysphagia, dysarthria, prominent chorea with motor impersistence and in advanced stages a hypokinetic rigid state accompanied by dementia, depression and psychosis. HD represents the neurological disease with the highest rates of depression and suicide.

Unfortunately there is no treatment that can cure or slow the course of the disease. Only modest symptomatic treatment options exist for those suffering from HD, mostly focused on ameliorating depression, psychosis, and chorea. Many therapeutical modalities, most of them including dopamine receptor blockers or dopamine depletors have been evaluated over the years, most of them in open label studies or presented as case reports. Few randomized double-blind studies with TBZ have been done in HD. ([@b35-ndt-3-545]; [@b50-ndt-3-545]; [@b68-ndt-3-545]; [@b17-ndt-3-545]).

Huntington's disease and tetrabenazine treatment
================================================

One of the main reasons for using TBZ instead of dopamine receptor blockers is its relative safety, exemplified by the fact that TBZ has never been documented as having caused tardive dyskinesia (TD). This is a major advantage of TBZ over the typical neuroleptics, since between 25%--40% of those chronically treated with DRBD eventually develop TD ([@b61-ndt-3-545]).

The first reports of the therapeutic potential of TBZ in patients with HD were published in the 1960's ([@b5-ndt-3-545]; [@b52-ndt-3-545]; [@b53-ndt-3-545]). Since the 1970's, numerous other clinical trials with relatively small numbers of patients have demonstrated the beneficial effects of TBZ for patients with chorea ([@b11-ndt-3-545]; [@b12-ndt-3-545]; [@b64-ndt-3-545]; [@b15-ndt-3-545]; [@b67-ndt-3-545]; [@b29-ndt-3-545]; Asher and Aminoff 1979; Jancovic 1982, 1983; Jancovic and Orman 1988; [@b13-ndt-3-545]; Jancovic and Beach 1997; [@b39-ndt-3-545]; [@b41-ndt-3-545]; [@b27-ndt-3-545]).

TBZ was approved for the treatment of chorea in the United Kingdom in 1971. It is also available in Canada and Australia, as well as in several European countries. TBZ is still unavailable in the United States, though it has been obtained by selected physicians via the Notice of Claimed Investigational Exemption for a New Drug (IND). However, in spite of its low availability, several long-term studies of TBZ in movement disorders, including HD, have been reported from the US.

There have been five major studies, which assessed the long-term efficacy of TBZ in chorea patients, most of them with HD. The most recent, a phase-III study assessing the safety, efficacy, and dose-tolerability of TBZ for ameliorating chorea in 84 patients with HD, was published by the Huntington Study Group (HSG) in 2006. HD patients were randomized to placebo (n = 30) or TBZ (n = 54) up to 100 mg/day at a titration rate of 12.5 mg per week. Based on the chorea score of the Unified Huntington Disease Rating Scale (UHDRS), TBZ significantly reduced the chorea score by 5.0 points compared to 1.5 for placebo (p \< 0.0001). Likewise, the CGIC showed significantly higher improvement rates in patients treated with TBZ in comparison to those given placebo. There were five withdrawals in the TBZ treatment group and five serious adverse events (SAE) including one suicide, which was felt to be due to situational depression rather than TBZ-induced depression. There were no SAE in the placebo group.

A retrospective chart analysis of 76 hyperkinetic patients in a pediatric population treated at Baylor College of Medicine from 1996--2004 revealed significant improvement in chorea in 89% of the patients (Vuong et al 2004).

In a study comprising 118 patients with hyperkinetic movement disorders (28 diagnosed with HD), patients were assessed by phone interview using the Clinical Global Impression of Change (CGIC) and the overall efficacy of treatment was shown via a composite score made up of the patient's score and the caregiver's score. Significant improvement of hyperkinesias was seen in 61% of patients, with a subgroup of subjects with chorea and facial dyskinesias responding most favorably ([@b41-ndt-3-545]).

In another small study of 19 HD patients treated with TBZ, the follow-up was carried out in a prospective fashion. The evaluation was done using the Abnormal Involuntary Movement Scale (AIMS), which was done by two separate investigators blinded to the drug administered. Eighteen patients completed and these patients were rated at 3.3 months at a final mean dose of 62.5 ± 37.4 mg/day. Fifteen patients scored better than before treatment, the scores of one remained the same and the scores of two others worsened ([@b39-ndt-3-545]).

The first published study assessing the long-term efficacy of TBZ in 400 hyperkinetic movement disorders patients selected from a large group of 526 included 29 HD patients. These patients improved by 82.8% on a scale of 1 to 5 (where 1 = improvement, 4 = no response and 5 = worsening). The average treatment duration was 28 ± 31.1 months (Jancovic and Beach 1997).

Kingston summarized the experience of 40 patients who had been receiving TBZ for almost 7 years for several movement disorders including chorea. 75% of these patients experienced marked or moderate improvement (Kingstone 1979).

A single-blind crossover study with a pretreatment phase, active drug, followed by placebo in 26 patients with HD, TD, and dystonia found that 54% experienced marked or moderate improvement of chorea with TBZ for the 3-week duration of the study (Asher and Aminoff 1979). Many studies that included a mixed group of movement disorders mention that the patients with chorea and TD responded better than patients with dystonia or tics.

A double-blind prospective crossover study of 20 patients assessed TBZ versus placebo for its effect on a variety of hyperkinetic movement disorders (Jancovic 1982). TBZ was found to improve the hyperkinesia score more than placebo to a statistically significant degree. Patients noted functional improvement, but this endpoint was not assessed in a quantitative manner. An open-label follow up of these same patients found that 62% of patients initially enrolled in the double-blind crossover study continued to display moderate improvement of the movement disorder 6--18 months later (Jancovic 1983). Major studies reporting on TBZ efficacy on chorea are summarized in [Table 2](#t2-ndt-3-545){ref-type="table"}.

Dosing issues
=============

TBZ is usually initiated at a dose of 12.5 mg twice a day and is slowly titrated in two or three divided doses up to 150--200 mg/day in increments of 25 mg/week. In studies and in daily practice, given the short half-life, dosing TID is sometimes necessary. The dose escalation is stopped when the patient experiences a clear therapeutic effect or intolerable side effects. This technique might indeed create a bias towards an increase in side effects in many clinical studies on TBZ as most studies are designed to increase the dose until intolerable side effects are noted and then the dose is slightly decreased to alleviate the side effects. Most drug-related side effects can be alleviated by lowering the dose. Overdose in a case of self-poisoning with tetrabenazine was described in a 27-year-old female without any significant sequelae, except for sedation, after taking approximately 1 gram of TBZ ([@b28-ndt-3-545]).

Tolerability and side effects
=============================

The most common immediate side effects include drowsiness/sedation, weakness, parkinsonism, depression and acute akathisia, all of which are reversible with decreased dosing (Jancovic 1997; [@b41-ndt-3-545]). Several studies have observed that younger patients tolerate TBZ better than the elderly. It is also notable that side effects vary slightly across different age groups: while younger patients showed a trend to experience more insomnia and depression, older patients seemed more likely to develop parkinsonism ([@b16-ndt-3-545]; [@b41-ndt-3-545]). Other rare side effects include: insomnia, nervousness/anxiety, nausea and vomiting, tremor, memory problems, confusion, "trance-like/zombie", orthostatic hypotension, balance and gait difficulties, dizziness, diarrhea, headaches, hallucinations, paresthesias, pharyngeal spasm and pain, blurred vision, panic attacks, paranoia (Jancovic and Beach 1997).

Changes in clinico-chemical tests during 12 months on TBZ were always minor, nearly always unsystematic and, on the whole, tended more towards a normalization of values. Even taking into account the limitations inherent in an uncontrolled trial, the conclusion was reached that long-term treatment with TBZ seems to be quite safe (Jancovic and Beach 1997). The extrapyramidal side effects of TBZ include parkinsonism, acute dystonia and akathisia and rarely neuroleptic malignant syndrome (NMS). It is particularly notable than not one single case of tardive dyskinesia has been reported with TBZ; it is this fact which confers its great advantage over dopamine receptor blockers. Concurrent use of antipsychotics with tetrabenazine can induce parkinsonism in HD patients ([@b37-ndt-3-545]) or acute dystonic reactions ([@b56-ndt-3-545]). In one of the NMS cases, factors potentiating NMS included a high dosage of tetrabenazine exceeding the accepted therapeutic range together with co-medication with the dopamine-synthesis inhibitor alpha-methylparatyrosine, while in an other case, abrupt introduction of the drug and discontinuation of concomitant neuroleptics may have contributed to this adverse reaction. Uneventful recovery occurred in both cases without the need for drugs specifically enhancing dopaminergic transmission, while rechallenge by tetrabenazine with conventional doses and slow upward titration was not followed by recurrence of the NMS ([@b6-ndt-3-545]; [@b34-ndt-3-545]; [@b40-ndt-3-545]). Other serious adverse events included pneumonia ([@b58-ndt-3-545]) severe dysphagia (Jancovic and Beach 1997), and suicide ([@b13-ndt-3-545]). While it is well known that depression is extremely prevalent in HD and that suicide rates for this population are among the highest of those for all neurological diseases, TBZ, while capable of potentiating depression, did not seem to be directly involved in the suicide cases or in any other fatalities which occurred during treatment.

Conclusion
==========

TBZ, a dopamine-depleting drug with a unique pharmacologic mechanism, has been found to be safe and efficacious for the treatment of a variety of hyperkinetic movement disorders, including HD. In the absence of modern disease modifying treatments for HD, symptomatic drug treatments such as TBZ remain important. These drugs, ideally, should be efficacious and devoid of debilitating side-effects.

Though most published studies are not double-blind, placebo-controlled trials, the sustained long-term benefit of patients speaks in favor of TBZ's clinical efficacy in HD. Furthermore, TBZ does not cause TD, which is its major advantage over dopamine receptor blockers. It also has generally well tolerated side effects that are usually dose-related and therefore resolvable by decreasing doses or employing slow titration. Potentially fatal side effects such as dysphagia and depression are rare, though their existence mandates close monitoring of patients.

Based on his observations and previous open studies demonstrating TBZ efficacy in chorea Mc Lellan may have rightfully affirmed that "tetrabenazine is the drug of first choice for the suppression of chorea in patients with Huntington's disease" ([@b35-ndt-3-545]).

![Tetrabenazine, a benzoquinolizine derivative with the chemical name, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo\[a\]quinolizine.](ndt-3-545f1){#f1-ndt-3-545}

###### 

Difference between tetrabenazine and reserpine

                          Tetrabenazine                       Reserpine
  ----------------------- ----------------------------------- ------------------------------------------------
  Monoamine depletion     Central through VMAT2               Central and peripheral through VMAT1 and VMAT2
  Binding                 Reversible                          Non-reversible
  Post-synaptic effects   YES(weak D2 blocker at high dose)   NO
  T1/2                    10 hrs                              Several days
  Side effects            NO                                  YES(gastrointestinal and hypotension)

###### 

Major studies in which chorea, including HD, patients were treated with TBZ showing treatment outcome

  Authors and year of publication   Number of patients                                         Outcome measures                         Outcome
  --------------------------------- ---------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------
  [@b17-ndt-3-545]                  84 HD patients                                             Reduction in chorea score of the UHDRS   5 point reduction in HD compared to 1.5 in placebo patients (p \< 0.0001)
  Vuong et al 2004                  76 pediatric patients                                      Chorea improvement by CGIC               89% of the patients improved
  [@b41-ndt-3-545]                  118 patients with hyperkinetic movement disorders, 28 HD   CGIC                                     61% of patients improved (chorea improved in 19/28 patients)
  [@b39-ndt-3-545]                  19 HD patients                                             AIMS                                     79% of patients improved (15/19)
  Jancovic and Beach 1997           400 hyperkinetic patients, 29 HD                           Modified CGIC (from 1--5)                Overall improved by 82.8% 97% of chorea patients improved (28/29)
  Jancovic 1982                     20 hyperkinetic patients                                   Functional                               62% of patients improved
  Asher and Aminoff 1979            26 patients with chorea, TD, tics                          Clinical                                 54% of chorea patients improved
  Kingstone 1979                    40 hyperkinetic patients                                   Clinical                                 75% marked to moderate improvement

**Abbreviation:** UHDRS, unified Huntington disease rating scale; CGIC, clinical global impression of change; AIMS, abnormal involuntary movement scale
